The rise of Viagra initially drove a surge for pharma, but recent changes present a complicated picture for those considering a stake. Off-patent versions are reducing earnings, and continued legal battles add further difficulty to the landscape. While certain companies may still gain from adjacent products, the broader trend suggests a wary approa